紫杉醇联合卡铂不同给药途径治疗卵巢癌的疗效观察  

Two Dosage Regimens of Paclitaxel Combined with Carboplatin in Treating Ovarian Cancer

作　　者：曾凡清[1] 吴南顺[1] 殷娟[1] 张蕾[1] 

机构地区：[1]重庆市第九人民医院妇科,重庆400700

出　　处：《中国药业》2015年第23期171-172,共2页China Pharmaceuticals

摘　　要：目的比较紫杉醇联合卡铂(IP方案)不同给药途径治疗卵巢癌的疗效。方法回顾性分析2010年5月至2012年5月收治的65例卵巢癌患者的临床资料,其中紫杉醇联合卡铂静脉化学治疗(简称化疗)33例(Ⅳ组,紫杉醇联合卡铂单纯静脉化疗),紫杉醇联合卡铂腹腔灌注32例(IP+Ⅳ组,紫杉醇静脉化疗联合卡铂腹腔化疗),观察两组近期疗效和不良反应。结果Ⅳ组和IP+Ⅳ组治疗有效率分别为63.64%和87.50%,差异有统计学意义(P<0.05);IP+Ⅳ组患者骨髓抑制发生率显著低于Ⅳ组,而胃肠道反应和肝毒性显著高于Ⅳ组(P<0.01)。结论紫杉醇与卡铂腹腔灌注联合静脉化疗效果良好,值得临床推广。Objective To investigate the effect of two dosage regimens of paclitaxel combined with carboplatin in treating ovarian cancer. Methods The clinical data of 65 patients with ovarian cancer from May 2010 to May 2012 were analyzed. Among them,33 patients received Ⅳ regimen and 32 patients received IP ＋ Ⅳ regimen. Short term clinical efficacy and adverse reactions of chemotherapy in two groups were observed. Results The effective rate in Ⅳ group and IP ＋ Ⅳ were 63. 64% and 87. 50% respectively（ P 〈 0. 05）.The marrow depression in IP ＋ Ⅳ group were significantly lower than that in Ⅳ group. The damage of gastrointestinal tract and liver function in IP ＋ Ⅳ group was significantly higher than that in Ⅳ group（ P 〈 0. 01）. Conclusion Intraperitoneal infusion with paclitaxel plus carboplatin is an effective way in treating ovarian cancer.

关 键 词：卵巢癌 紫杉醇 卡铂 

分 类 号：R969.4[医药卫生—药理学] R979.1[医药卫生—药学]